Cash/Burn From Filing For Period: 

Q3 '19

NKTR

Nektar Therapeutics

We are a clinical-stage biopharmaceutical company with a proven track record of discovering and developing new medicines that treat patients living with debilitating diseases and conditions. We build on a chemistry platform that was invented in our labs along with our scientific expertise to focus on developing unique and more precise medicines.

Cash

$1.50B

Burn Rate

$98.8M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Bempegaldesleukin + OPDIVO

Muscle-invasive Bladder Cancer

Phase 3

Bempegaldesleukin + OPDIVO

Renal Cell Carcinoma

Phase 3

NKTR 214 + Opdivo

Melanoma

Phase 3

Onzeald

Advanced Breast Cancer and Brain Metastases

Phase 3

Dapirolizumab Pegol

Systemic lupus erythematosus (SLE)

Phase 2

Bempegaldesleukin + OPDIVO

Immuno-oncology

Phase 2

Bempegaldesleukin + OPDIVO

Urothelial Cancer

Phase 2

Bempegaldesleukin + VB10.NEO

Squamous Cell Carcinoma of the Head and Neck

Phase 1/2

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon